Progyny, Inc. (NASDAQ:PGNY – Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday after Leerink Partners lowered their price target on the stock from $25.00 to $21.00. Leerink Partners currently has a market perform rating on the stock. Progyny traded as low as $18.40 and last traded at $18.40, with a volume of 214782 shares changing hands. The stock had previously closed at $24.44.
A number of other equities analysts also recently weighed in on the company. BTIG Research downgraded Progyny from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Truist Financial dropped their price objective on shares of Progyny from $37.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Canaccord Genuity Group lowered shares of Progyny from a “buy” rating to a “hold” rating and decreased their target price for the company from $37.00 to $24.00 in a research note on Wednesday, August 7th. JMP Securities downgraded shares of Progyny from an “outperform” rating to a “market perform” rating in a research note on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $37.00 price objective on shares of Progyny in a report on Tuesday, August 20th. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.50.
View Our Latest Analysis on Progyny
Insider Buying and Selling
Institutional Trading of Progyny
Hedge funds have recently added to or reduced their stakes in the business. Quarry LP lifted its holdings in shares of Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after buying an additional 836 shares during the last quarter. TFC Financial Management Inc. bought a new stake in Progyny in the 1st quarter valued at $42,000. Financial Management Professionals Inc. acquired a new stake in Progyny in the 1st quarter worth $52,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Progyny during the 2nd quarter worth about $44,000. Finally, Cambridge Trust Co. bought a new position in shares of Progyny during the 1st quarter worth about $95,000. Institutional investors own 94.93% of the company’s stock.
Progyny Stock Down 30.7 %
The firm has a market cap of $1.61 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 1.88 and a beta of 1.45. The stock’s 50-day moving average price is $24.62 and its 200 day moving average price is $28.90.
Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, hitting analysts’ consensus estimates of $0.17. The company had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $0.15 EPS. On average, research analysts predict that Progyny, Inc. will post 0.64 EPS for the current year.
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
- Five stocks we like better than Progyny
- 3 Grocery Stocks That Are Proving They Are Still Essential
- What’s Next After FOMC’s Aggressive Interest Rate Cuts?
- What is the Australian Securities Exchange (ASX)
- Verizon Stock: 5G Boom and Robust Dividend Yield at Play
- Best Aerospace Stocks Investing
- 3 Stocks with Upgraded Ratings: Analysts Predict More Upside
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.